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months) between an innovative product’s FDA and EMA approval. Average time to 
reimbursement in the EU5 after the EMA approval ranges from 7.0-11.2 months. 
Pharmaceutical companies need to plan ahead and submit the application dossier 
as early as possible to achieve faster access, especially for oncology products. Early 
access programmes, such as ATU in FRA and Cnn in ITA, may also be considered 
in certain countries.
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Objectives: Health care utilization is likely to be conditioned to socioeconomic 
factors. The aim of this study is to identify the impact of these determinants, as 
well as the health perception variables in the use of the health services in the 
Mexican population. MethOds: Data from the National Health Survey 2012 was 
used to identify social, economic and health perception variables among users of 
the ambulatory and hospital care services. Statistical analysis was performed to 
test significant differences among users in relation to gender, equivalent household 
income and age data. A Probit model was used to identify and measure the impact 
of these variables on the utilization of the ambulatory care services among patients 
and a Poisson model for modelling the number of hospitalizations. Results: 8.48% 
of the population used ambulatory services during the last two weeks and 3.89% 
required hospitalization at least once during the last year. Significant statistical 
differences were observed between gender, income and age with the ambulatory 
and hospital care use. The results from the Probit model showed that men are less 
likely to use ambulatory services compared to women, as well as individuals at 
younger ages (0-9 years) (Z= 7.95). Additionally, at higher income deciles, a positive 
significant impact was found for using this service. The Poisson model revealed that 
education, employment and medical insurance are statistically significant variables 
with positive impact on the times people are hospitalized. Finally, other variables 
with a positive impact on both types of care are morbidity and the illness percep-
tion mainly when this is severe. cOnclusiOns: In addition to the influence of 
socioeconomic and demographic factors, health perceptions among patients are 
significant determinants that explain the decision and frequency of the health care 
utilization in the Mexican population.
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Objectives: Public expenditure on health on India is around 1% of GDP and 
79% expenditure in health of people is through out-of-pocket. Almost 30 % of the 
households slide into poverty due to high treatment costs and medicines. Though, 
India is considered as pharmacy for developing countries, yet due to poor regu-
latory control there is huge price variation in off-patent branded generics, even 
50 times or more and leaving affordability at the mercy of prescribers/dispens-
ers. MethOds: The Government of Rajasthan (a federal State in India with popu-
lation about 70 million) has launched a scheme called Chief Minister’s Free Drug 
Distribution Scheme (CMFDDS) for providing free essential medicines to all irre-
spective of their economic status through establishing an autonomous Rajasthan 
Medical Services Corporation (RMSC). By well-defined transparent prequalification 
measures for products and suppliers, RMSC procures quality medicines through 
cost-minimization. Educational, managerial and regulatory strategies have been 
used to promote compliance by stakeholders Results: Quality essential medi-
cines are procured at unbelievable low cost compared to market retail prices, e.g. 
procurement cost / market retail prices for strip of 10 tablets of DICLOFENAC 50 
mg, ATORVASTATIN 10 mg, GLIMEPIRIDE 2 mg, and CLOPIDOGREL 75 mg are INR 
1.24/31.73, 2.98/103.74, 1.95/125.00 and 8.54/147.44 respectively (1 USD= INR 63) 
resulting an increase in access and equity with monthly patient inflow increased 
from 44,000,00 to 66,000,000 and decrease/elimination in out of pocket expenditure, 
as amount spent on medicines in 2 years is around INR 5,070,000,000 whereas mar-
ket price of these medicines would be. INR 30,000,000,000. cOnclusiOns: Essential 
medicines are not costly but are being made expensive. By utilizing the pricing 
information of quality medicines along with transparent pooled procurement and 
proper distribution system can make free access to medicines, especially under-
served population with a strong political commitment coupled with the proper 
strategies in low resource settings.
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Objectives: There is a growing need for the development of real-world clinical evi-
dences, particularly in the field of health technology assessments. The objective of 
this analysis was to identify and describe the key elements for the implementation 
of a program aiming to develop real-world clinical evidences in Quebec. MethOds: 
A literature review was conducted to analyze the position, progress and devel-
opment of strategies fostering risk management and development of real-world 
clinical evidences in different provinces and countries. A literature search was 
performed using electronic databases including Pubmed, Medline and Embase. 
Additional guidelines and government policies were retrieved using Google and 
Google Scholar. The following keywords, were used for search, alone or in combina-
tion: risk-sharing and product listing agreements, coverage with evidence devel-
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Objectives: Prescription claims databases are commonly used for identifying 
patients for disease management programs, studying health outcomes and report-
ing on quality measures. A shortcoming of claims databases for these purposes is 
that they include only prescriptions that are adjudicated through insurance plans. 
Growth in the use of cash discount generic programs and the frequent use of drug 
samples suggests that an increasing number of prescriptions dispensed to insured 
consumers may not be captured on claims databases. We examined the extent to 
which prescription claims databases do not provide complete records of insured 
patients’ prescription drug use. MethOds: We used the 2009 Medical Expenditure 
Panel Survey (MEPS) dataset. We included participants who purchased at least one 
prescription medication and who had prescription drug insurance for all of 2009. We 
quantified the extent to which insured patients used drug samples, drugs paid for 
by cash only, and/or discount generics. We measured the numbers of prescriptions 
in each of these categories and the numbers of consumers who had at least one 
prescription in each category. We reported descriptive statistics. Results: A total of 
75.1% of the U.S. non-institutionalized civilian population was insured for prescrip-
tion drugs. Of the total number of prescriptions dispensed to insured consumers, at 
least 0.8% were drug samples and 23.3 % were paid for by cash, of which 11.3% were 
potentially discount generics. Additionally, 11.6 % of insured consumers received 
at least one sample medication, 68.0% paid for at least one of their prescribed 
medications by cash, of which 42.5% used at least one potential discount generic 
product. cOnclusiOns: Our results indicate that drug samples do not contribute 
substantially to the problem of missing prescription data on claims databases. On 
the other hand, substantial number of prescriptions, paid for by cash and discount 
generics, may be missing from these databases.
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Objectives: To compare adherence to prescribed medications between patients 
with differed and those with immediate reimbursement at the point of service 
among Quebecers (Canada) with private drug insurance. MethOds: A retrospec-
tive cohort was constructed by selecting patients aged 18-64 years with private 
drug insurance from the reMed database between March 2008 and December 2012. 
An algorithm was developed to assess the patient’s reimbursement modality, i.e. 
the drug cost covered by the insurance company is reimbursed immediately at the 
point of service (immediate reimbursement) or at a later time (differed reimburse-
ment). Adherence was measured with the proportion of days covered (PDC) over one 
year for new users of the five most dispensed classes of medications, i.e. statins, 
proton pump inhibitors, thyroid hormones, antidepressants, and antihypertensive 
medications. Linear regression models were used to estimate the adjusted mean 
difference of the PDC between the two groups for each drug class. Results: The 
cohort included 6,494 patients with immediate and 1,950 patients with differed 
drug reimbursement. More than 40% of patients were 35-49 years, 26% were men 
and 85% were past or non-smokers. The mean PDC was 79.9 % for patients with 
immediate reimbursement and 89.3 % for patients with differed reimbursement 
among new users of statins. Corresponding figures were 48.3% and 45.1% for new 
users of proton pump inhibitors, 84.7% and 84.8% for new users of thyroid hormones, 
67.1% and 66.8% for new users of antidepressants, and 68.4% and 73.5% for new 
users of antihypertensive medications. The results of the linear regression analyses 
showed no significant differences between patients with immediate and differed 
drug reimbursement. cOnclusiOns: Patient’s adherence was low for several drug 
classes but appeared to be unaffected by differed reimbursement. The short period 
of time between the purchase of the medication and the reimbursement by the 
insurer might explain the results.
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Objectives: The purpose of this study was to estimate the time difference between 
the FDA and EMA approvals, as well as time to reimbursement in the UK, GER, 
FRA, ESP and ITA after EMA approval. MethOds: 32 high-cost drugs that were 
approved by both the FDA and EMA in 2011-2013 were assessed. Two-thirds of the 
sample were oncology drugs; the remaining one third included drugs treating other 
specialty diseases. Out of 32 drugs, 17 have obtained reimbursement from all EU5 
countries. Time of reimbursement was defined as the date of publication of SMC 
guidelines in SCT, NICE Final Appraisal Determination in ENG, CT decision in FRA, 
G-BA decision in GER, AIFA decision in ITA and AEMPS decision in ESP. Results: 
The average time difference between the FDA and EMA approvals (USA-EU approval 
interval) was 5.9 months (standard deviation (SD) 5.2 months), similar to the median 
USA-EU approval interval (6 months). The average time to reimbursement after EMA 
approval varies from 211 days in SCT (SD 75.9 days) to 336 days in ESP (SD 203 days). 
On average, the USA-EU approval interval for oncology drugs was almost twice as 
long as for non-oncology drugs (7.0 vs. 3.8 months), but there was minimal differ-
ence in time to reimbursement for oncology versus non-oncology drugs in the EU5, 
except in ESP, where the reimbursement decision for non-oncology drugs was 112 
days faster than for oncology drugs. cOnclusiOns: There is still a long gap (5.9 
